公开(公告)号：US20250020667A1

公开(公告)日：2025-01-16

申请号：US18808814

申请日：2024-08-19

Applicant: Baylor College of Medicine

Inventor： Robert Allen Britton ,  Jeffrey David Galley

IPC: G01N33/68 ,  C12Q1/02 ,  C12Q1/6897

Abstract: Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.

公开(公告)号：US20190270790A1

公开(公告)日：2019-09-05

申请号：US16348443

申请日：2017-11-09

Applicant: Baylor College of Medicine

Inventor： Robert Allen Britton ,  Catherine Tomaro-Duchesneau

IPC: C07K14/605 ,  A61P1/00 ,  A61P3/04

Abstract: Embodiments of the disclosure encompass compositions and methods for the treatment of medical conditions in which increases in GLP-1 are beneficial to an individual. In specific embodiments, the disclosure concerns certain peptides that are capable of inducing GLP-1 production in an individual with a medical condition, such as type II diabetes or obesity. In other cases, an individual is not obese or overweight but is provided the peptide in an effort to reduce weight from fat.

公开(公告)号：US11028141B2

公开(公告)日：2021-06-08

申请号：US16348443

申请日：2017-11-09

Applicant: Baylor College of Medicine

Inventor： Robert Allen Britton ,  Catherine Tomaro-Duchesneau

IPC: A61K38/16 ,  A61K38/00 ,  A61P1/00 ,  A61P3/04 ,  C07K14/605

Abstract: Embodiments of the disclosure encompass compositions and methods for the treatment of medical conditions in which increases in GLP-1 are beneficial to an individual. In specific embodiments, the disclosure concerns certain peptides that are capable of inducing GLP-1 production in an individual with a medical condition, such as type II diabetes or obesity. In other cases, an individual is not obese or overweight but is provided the peptide in an effort to reduce weight from fat.

公开(公告)号：US20200209261A1

公开(公告)日：2020-07-02

申请号：US16612590

申请日：2018-05-11

Applicant: Baylor College of Medicine

Inventor： Robert Allen Britton ,  Jeffrey David Galley

IPC: G01N33/68 ,  C12Q1/02 ,  C12Q1/6897

Abstract: Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.

公开(公告)号：US20200269230A1

公开(公告)日：2020-08-27

申请号：US16757577

申请日：2018-10-26

Applicant: Baylor College of Medicine ,  William Marsh Rice University

Inventor： Tatiana Y. Fofanova ,  Jennifer Auchtung ,  Reid Laurence Wilson ,  Christopher Stewart ,  Joseph Petrosino ,  Robert Allen Britton ,  Jane Grande-Allen ,  Noah F. Shroyer ,  Mary K. Estes

IPC: B01L1/02 ,  B01L3/00 ,  C12Q1/18 ,  C12Q1/70 ,  G01N33/50

Abstract: An anaerobic chamber system to evaluate human enteric disease is described herein that can be used to test therapeutic components. In specific embodiments, the anaerobic chamber is used to determine the effect of one or more bacterial communities on ex vivo enteroid cultures. In one application, the anaerobic chamber system is used to determine the efficacy of therapeutic components in ameliorating human enteric disease using personalized medicine.

公开(公告)号：US20200054697A1

公开(公告)日：2020-02-20

申请号：US16604013

申请日：2018-04-11

Applicant: Baylor College of Medicine

Inventor： Cintia S. De Paiva ,  Stephen C. Pflugfelder ,  Robert Allen Britton

IPC: A61K35/747 ,  A61P27/04 ,  A61P37/06

Abstract: Embodiments of the disclosure encompass methods of treating or preventing an autoimmune disease in an individual. In particular cases, methods comprise administering for delivery to an individual a composition of microbiota. In certain cases, the composition comprises a population of one or more microbiota capable of producing one or more short-chain fatty acids.